C2N at AAIC in Philadelphia July 28–Aug. 1
C2N Diagnostics, a leader in advanced brain health diagnostics, is adding to its evidence-based legacy at the 2024 Alzheimer’s Association International Conference (AAIC) in Philadelphia July 28 – August 1
C2N continues to set a standard in innovation in Alzheimer’s disease diagnostics through numerous presentations by esteemed researchers and clinicians at AAIC. Join us in Philadelphia and be among the first to learn about exciting new data for the Precivity™ line of blood tests.
Please visit our new dynamic C2N booth. When entering the exhibit hall entrance, head to the left and look for our signage – Booth #1313. We encourage you to click this link to schedule a meeting with our team.
Sessions on C2N'S Test Data
16 sessions and 9 posters will offer novel insights relating to the Precivity™ blood tests. These presentations/posters include:
Product Theater Presentation
Wednesday, July 31 12:25 p.m. – 1:05 pm EDT in the Exhibit Hall
Hear Dr. Joel Braunstein, CEO and Dr. Sheena Aurora, Vice President of Neurology, C2N speak to: C2N's Pursuit of Transforming the Diagnostic Odyssey
Sunday, July 28
9:45 a.m. – 10:00 a.m. EDT
Ballroom A
Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease
2:00 p.m. – 2:15 p.m. EDT
Hall A
Evaluation of the prospective use of blood biomarkers for Alzheimer’s disease in primary and secondary care
2:50 p.m. – 3:00 p.m. EDT
118 ABC
Predicting PET-based amyloid and tau pathology stages with plasma biomarkers in Alzheimer's disease
Monday, July 29
2:20 p.m. – 2:30 p.m. EDT
115 ABC
Pragmatic considerations in clinical biomarker testing for Alzheimer’s disease
2:40 p.m. – 2:50 p.m. EDT
115 ABC
Real world implementation of blood biomarkers in primary care
Tuesday, July 30
2:00 p.m. – 3:30 p.m. EDT
Hall A
Long-Term Effects of Lecanemab on Biomarkers of Neurodegeneration in Plasma
2:28 p.m. – 2:35 p.m. EDT
118 ABC
Head-to-head evaluation of leading blood tests for amyloid pathology
2:49 p.m. – 2:56 p.m. EDT
118 ABC
Lecanemab slows amyloid-induced tau pathology as supported by CSF MTBR-tau243 in ClarityAD
Wednesday, July 31
8:00 a.m. – 8:07 a.m. EDT
118 ABC
Data from Phase2/3 Clinical Study in Mild to Moderate Alzheimer's Disease
9:30 a.m. – 9:40 a.m. EDT
120 ABC
Potential of dual orexin receptor antagonists to prevent Alzheimer's disease
Thursday, August 1
10:10 a.m. – 10:20 a.m. EDT
118 ABC
Modeling the temporal evolution of mass spectrometry plasma biomarkers
10:50 a.m. – 11:00 a.m. EDT
118 ABC
Effect of kidney function on plasma pTau217 concentrations using different pTau217 assays
All sessions will be held at the Philadelphia Convention Center.
Poster Sessions
Sunday, July 28
Use of a blood-based amyloid test for screening in INVOKE-2: a phase 2 randomized, double-blind, placebo-controlled study evaluating AL002 in early Alzheimer’s disease
Biomarker evaluation in young onset dementia from diverse populations
Impact of a high-performing blood test on wait times for determination of eligibility for a disease-modifying Alzheimer’s treatment in the U.S.
Monday, July 29
Diagnostic performance of plasma biomarkers for A/T/N image classification in Alzheimer's disease
Prediction of regional brain tau levels in early Alzheimer’s disease using plasma p-tau217
Tuesday, July 30
The EEG spectral power ratio as a cognitively relevant marker of preclinical AD
Wednesday, July 31
Consistent classification of amyloid status by fasted and non-fasted plasma Aβ42/40 and Amyloid Probability Score
Other AAIC Sessions on Blood Biomarkers Relating to the Precivity Tests from the Laboratory of Dr. Randall Bateman, Washington University, St Louis MO
Sessions
Sunday, July 28
9:00 a.m. – 9:12 a.m. EDT
Ballroom A
P-tau217 significance as marker of brain amyloid-beta and tau pathologies
2:15 p.m. – 2:30 p.m. EDT
Hall A
Alzheimer’s disease blood tests of amyloid-beta 42/40, %p-tau217, 181, and 205 ratios and MTBR-243 in real-world populations: Results from SEABIRD and BioFINDER2
On Demand Sessions
A combination of plasma phospho-tau217 and Aβ42/40 detects early development of amyloid pathology in cognitively unimpaired individuals
Improved precision of Alzheimer’s disease fluid biomarkers when using Amyloid-β40 or non-phosphorylated tau as a reference
Posters
Sunday, July 28
A highly accurate blood test for Alzheimer’s disease pathology has performance equivalent or superior to clinically used CSF tests
Tuesday, July 28
Head-to-head comparison of four plasma phosphorylated tau 217 biomarkers
We encourage you to click this link to schedule a meeting with our team. We look forward to seeing you in Philadelphia!
About C₂N Diagnostics, LLC
C₂N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation™. C₂N strives to provide exceptional laboratory services and products in the field of brain health. C₂N’s biomarker services and products are used for: clinical decision making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. For more information visit www.C2N.com.